[Skip to Content]
[Skip to Content Landing]
From the JAMA Network
February 2017

Preserving Neurocognition in Patients With Brain Metastases

Author Affiliations
  • 1Department of Radiation Oncology, Keck School of Medicine of University of Southern California, Los Angeles
JAMA Oncol. 2017;3(2):269-270. doi:10.1001/jamaoncol.2016.3944

Historically, whole brain radiation therapy (WBRT) has served as the mainstay in the treatment of brain metastases over the past 65 years and is administered with 2 goals in mind: (1) to provide effective palliation of symptomatic brain metastases and (2) to sterilize occult microscopic disease. In the past 2 decades, WBRT has been used in the adjuvant setting following surgery to improve local control at the resection cavity and distant control in the brain. Following the adoption of stereotactic radiosurgery (SRS) for the treatment of brain metastasis in the mid-1990s, WBRT also has been used with SRS as an adjuvant treatment with similar goals in mind.